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Articles
Immunogenicity of chimeric haemagglutinin-based, 
universal influenza virus vaccine candidates: interim results 
of a randomised, placebo-controlled, phase 1 clinical trial
David I Bernstein, Jeffrey Guptill, Abdollah Naficy, Raffael Nachbagauer, Francesco Berlanda-Scorza, Jodi Feser, Patrick C Wilson, Alicia Solórzano, 
Marie Van der Wielen, Emmanuel B Walter, Randy A Albrecht, Kristen N Buschle, Yao-qing Chen, Carine Claeys, Michelle Dickey, Haley L Dugan, 
Megan E Ermler, Debra Freeman, Min Gao, Christopher Gast, Jenna J Guthmiller, Rong Hai, Carole Henry, Linda Yu-Ling Lan, Monica McNeal, 
Anna-Karin E Palm, Dustin G Shaw, Christopher T Stamper, Weina Sun, Victoria Sutton, Micah E Tepora, Rahnuma Wahid, Heather Wenzel, 
Teddy John Wohlbold, Bruce L Innis, Adolfo García-Sastre, Peter Palese, Florian Krammer
Summary
Background Influenza viruses cause substantial annual morbidity and mortality globally. Current vaccines protect 
against influenza only when well matched to the circulating strains. However, antigenic drift can cause considerable 
mismatches between vaccine and circulating strains, substantially reducing vaccine effectiveness. Moreover, current 
seasonal vaccines are ineffective against pandemic influenza, and production of a vaccine matched to a newly 
emerging virus strain takes months. Therefore, there is an unmet medical need for a broadly protective influenza 
virus vaccine. We aimed to test the ability of chimeric H1 haemagglutinin-based universal influenza virus vaccine 
candidates to induce broadly cross-reactive antibodies targeting the stalk domain of group 1 haemagglutinin-
expressing influenza viruses.
Methods We did a randomised, observer-blinded, phase 1 study in healthy adults in two centres in the USA. Participants 
were randomly assigned to one of three prime–boost, chimeric haemagglutinin-based vaccine regimens or one of two 
placebo groups. The vaccine regimens included a chimeric H8/1, intranasal, live-attenuated vaccine on day 1 followed 
by a non-adjuvanted, chimeric H5/1, intramuscular, inactivated vaccine on day 85; the same regimen but with the 
inactivated vaccine being adjuvanted with AS03; and an AS03-adjuvanted, chimeric H8/1, intramuscular, inactivated 
vaccine followed by an AS03-adjuvanted, chimeric H5/1, intramuscular, inactivated vaccine. In this planned interim 
analysis, the primary endpoints of reactogenicity and safety were assessed by blinded study group. We also assessed 
anti-H1 haemagglutinin stalk, anti-H2, anti-H9, and anti-H18 IgG antibody titres and plasmablast and memory B-cell 
responses in peripheral blood. This trial is registered with ClinicalTrials.gov, number NCT03300050.
Findings Between Oct 10, 2017, and Nov 27, 2017, 65 participants were enrolled and randomly assigned. The adjuvanted 
inactivated vaccine, but not the live-attenuated vaccine, induced a substantial serum IgG antibody response after the 
prime immunisation, with a seven times increase in anti-H1 stalk antibody titres on day 29. After boost immunisation, 
all vaccine regimens induced detectable anti-H1 stalk antibody (2·2–5·6 times induction over baseline), cross-reactive 
serum IgG antibody, and peripheral blood plasmablast responses. An unsolicited adverse event was reported for 
29 (48%) of 61 participants. Solicited local adverse events were reported in 12 (48%) of 25 participants following prime 
vaccination with intramuscular study product or placebo, in 12 (33%) of 36 after prime immunisation with intranasal 
study product or placebo, and in 18 (32%) of 56 following booster doses of study product or placebo. Solicited systemic 
adverse events were reported in 14 (56%) of 25 after prime immunisation with intramuscular study product or placebo, 
in 22 (61%) of 36 after immunisation with intranasal study product or placebo, and in 21 (38%) of 56 after booster doses 
of study product or placebo. Disaggregated safety data were not available at the time of this interim analysis.
Interpretation The tested chimeric haemagglutinin-based, universal influenza virus vaccine regimens elicited cross-
reactive serum IgG antibodies that targeted the conserved haemagglutinin stalk domain. This is the first proof-of-
principle study to show that high anti-stalk titres can be induced by a rationally designed vaccine in humans and 
opens up avenues for further development of universal influenza virus vaccines. On the basis of the blinded study 
group, the vaccine regimens were tolerable and no safety concerns were observed.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Introduction
Seasonal influenza viruses cause up to 650 000 deaths 
and 3–5 million severe infections annually worldwide.1 
Current vaccines protect well against influenza when 
they match circulating strains, but must be updated and 
re-administered annually because of antigenic drift of 
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the virus. Annual strain selection for seasonal vaccines is 
based on predictions, therefore mismatches often occur, 
leading to a substantial decrease in vaccine effectiveness. 
Additionally, pandemics occur in irregular intervals 
causing substantial morbidity and mortality. Matched 
vaccines have to be manufactured for these emerging 
viruses, a process that takes about 6 months,2 during 
which time the population remains vulnerable. A vaccine 
that protects against influenza independently of antigenic 
drift or shift is, therefore, urgently needed, as emphasised 
by the National Institute of Allergy and Infectious 
Diseases.3–5
The majority of the antibody response induced by 
seasonal vaccines is directed towards the immuno- 
dominant head domain of haemagglutinin, which has 
high plasticity and is responsible for most of the antigenic 
drift.6,7 The membrane proximal stalk domain of haema-
gglutinin is highly conserved but immuno- subdominant, 
and it is not readily targeted by the immune system. 
However, both memory B cells targeting the stalk and 
low anti-stalk antibody titres have been detected in 
adults.8–10 Monoclonal haemagglutinin stalk-specific 
antibodies isolated from mice and humans show broad 
in-vitro neutralisation of influenza virus subtypes (but no 
haemagglutination-inhibiting activity), usually restricted 
to one of the two types of influenza A virus 
hemagglutinins, group 1 (H1, H2, H5, H6, H8, H9, H11, 
H12, H13, H16, H17, and H18) or group 2 (H3, H4, H7, 
H10, H14, and H15).11 Passive immunisation of animals 
with stalk-reactive antibodies protected them from 
challenge with both seasonal and avian influenza virus 
strains and subtypes within the same haemagglutinin 
group.11
We have designed a vaccination strategy to selectively 
induce high concentrations of anti-stalk antibodies using 
sequential vaccination with chimeric haemagglutinin 
constructs (figure 1A). These constructs consist of 
H1 (group 1), H3 (group 2), or influenza B virus 
haemagglutinin stalks combined with head domains to 
which humans are naive.13–15 In mouse and ferret influenza 
vaccination and challenge models, sequential vaccination 
with chimeric haemagglutinins that featured the same 
(eg, H1) stalk but different head (eg, H5 and H8) domains 
induced strong anti-stalk responses, with relatively weaker 
responses to the respective head domains, protecting them 
from challenge with diverse influenza viruses.16–19 This 
response is achieved because immunity to the stalk is first 
primed and subsequent vaccinations lead to recall 
responses against the stalk, which the immune system has 
already seen. However, the different heads are antigenically 
Research in context
Evidence before this study
PubMed was searched with the terms “universal influenza virus 
vaccine”, “hemagglutinin stalk”, “influenza heterosubtypic 
immunity”, and “anti-stalk antibody”, without language 
restrictions, for literature published between database 
inception and March 21, 2019. The first paper regarding a 
broadly protective haemagglutinin stalk-reactive antibody was 
published in 1993; similar antibodies were then discovered for 
the first time in humans in 2008. The existence of these 
antibodies in humans suggested that designing a universal 
influenza virus vaccine might be feasible. Several 
haemagglutinin stalk-based vaccines have been preclinically 
tested since then, including the chimeric haemagglutinin 
candidates evaluated in this study. Preclinical experiments with 
chimeric haemagglutinin constructs showed that priming with 
a live-attenuated virus vaccine followed by boosting with an 
inactivated, adjuvanted virus vaccine (both expressing 
chimeric haemagglutinins with the same stalk but different 
head domains) provided excellent protection. This finding 
formed the basis of the phase 1 study reported here. Several 
clinical trials with broadly protective influenza virus vaccine 
candidates based on internal viral proteins or peptides that 
trigger T-cell responses have been reported, but no clinical data 
exist for stalk-based vaccine approaches. As emphasised by 
the US National Institutes of Health, the Bill & Melinda Gates 
Foundation, and European funding agencies, improved and 
preferentially universal influenza virus vaccines are urgently 
needed.
Added value of this study
This is the first study to report testing of a haemagglutinin 
stalk-based universal influenza virus vaccine in humans. 
The different vaccination regimens tested induced high titres of 
anti-haemagglutinin stalk serum IgG antibodies, but the 
strength of induction varied between regimens. The induction 
was strongest with inactivated, AS03-adjuvanted vaccines. 
The induced antibodies, independently of the vaccination 
regimen, bound broadly to heterosubtypic group 1 influenza 
virus haemagglutinins, including H2, H9, and H18. Our data 
suggest that rationally designed antigens and vaccine regimens 
can induce stalk-directed heterosubtypic antibodies in adults 
and pave the way for further clinical development of our 
vaccine candidates.
Implications of all available evidence
This study provides evidence that group 1 (eg, H1, H2, and H5) 
chimeric haemagglutinin-based universal influenza virus vaccines 
can induce high serum titres of anti-haemagglutinin stalk IgG 
with heterosubtypic group 1 cross-reactivity. This result suggests 
that group 2 (eg, H3 and H7) constructs, which are in preclinical 
development, might induce similar immune responses. In more 
general terms, our findings provide evidence that stalk-based 
immunogens can induce high titres of cross-reactive antibodies. 
This evidence opens up opportunities for the clinical development 
of urgently needed broadly protective or universal influenza virus 
vaccines that might provide protection from drifted seasonal, 
zoonotic, and emerging pandemic influenza virus infection.
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distinct from one another and elicit only primary responses 
(figure 1A). With this approach, we hypothesise that a 
set of trivalent chimeric haemagglutinin-based vaccines 
directing an immune response to the H1 or group 1, H3 or 
group 2, and influenza B virus stalks could confer universal 
protection against influenza A and B. In this study, we have 
used monovalent H1 (group 1) chimeric haemagglutinin 
vaccines to test this concept.
Specifically, we tested whether stalk antibodies in adults 
with pre-existing immunity to influenza virus haema- 
gglutinin8 could be boosted using chimeric H8/1 and 
H5/1 constructs (figure 1A). Two approaches were tested. 
The first included an initial vaccination with a live-
attenuated influenza virus vaccine (LAIV) expressing 
chimeric H8/1 and neuraminidase subtype 1 (N1) 
followed by a chimeric H5/1N1 split virion inactivated 
influenza virus vaccine (IIV) boost given with or without 
AS03 adjuvant.20 The second approach included vacci-
nation with AS03-adjuvanted chimeric H8/1N1 IIV 
followed by a boost with AS03-adjuvanted chimeric 
H5/1N1 IIV. The heterologous prime–boost regimen 
comprised of the LAIV followed by the IIV was tested 
because it was previously shown to induce optimal 
antibody responses with avian or pre-pandemic influenza 
virus vaccines in humans and non-human primates 
and with chimeric haema gglutinin-based vaccines in 
ferrets.18,21–24 In studies in ferrets,18,25 we observed that 
the chimeric haemagglutinin-based LAIV–IIV regimen 
induced protection against infection that was superior to 
the protection observed with chimeric haemagglutinin 
IIV–IIV regimens. This observation led to the hypothesis 
tested in this trial that administration of a chimeric 
haemagglutinin-based LAIV through the intranasal route 
as the first dose in a prime–boost immunisation 
sequence, followed by a chimeric haemagglutinin-based 
IIV boost via the intramuscular route, might offer 
superior immunogenicity compared with two intra-
muscular doses of the chimeric IIV.
Methods
Study design and participants
We did a randomised, placebo-controlled, observer-
blinded, phase 1 study at Cincinnati Children’s Hospital 
Medical Center (Cincinnati, OH, USA) and the Duke 
Early Phase Clinical Research Unit (Durham, NC, 
USA), with participants recruited from the community. 
Figure 1: Schematic of the chimeric HA vaccination regimens and trial design
(A) Vaccination strategy. Adults have pre-existing antibodies targeting both the 
membrane-distal head domain (top) and the membrane-proximal stalk domain 
(bottom) of H1 HA (green) due to previous exposure to influenza viruses. 
Vaccination with a chimeric H8/1 construct is expected to elicit some antibodies 
against the head domain (yellow), to which humans are naive, while 
substantially boosting H1 stalk antibodies. An additional booster vaccination 
with chimeric H5/1 HA was expected to provide an additional increase in 
antibodies targeting the HA stalk domain. Structures were adapted from RCSB 
Protein Data Bank ID 1RU7 and visualised in Protein Workshop.12 (B) Vaccination 
and blood collection schedule. (C) A phylogenetic tree based on percentage 
amino acid difference was constructed to illustrate the evolutionary distance of 
the antigens used for the ELISA analysis. The H1 (blue) stalk domain was used in 
the vaccines. H2 is closely related to H1, whereas H9 and H18 (all highlighted in 
green) are distantly related HAs within influenza A group 1. HA subtypes that 
donated heads to the vaccine constructs (H5 and H8) are shown in purple. 
Group 1 HAs are shaded in purple and group 2 in orange. HA clades are indicated 
within the groups. The scale bar represents a 5% difference in amino acid 
sequence. IIV=inactivated influenza vaccine. LAIV=live-attenuated influenza 
vaccine. PBS=phosphate-buffered saline. HA=haemagglutinin.
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Enrolment began on Oct 10, 2017, and participants 
remained in follow-up until Aug 9, 2019.
Healthy men or non-pregnant women aged 18–39 years 
who were either of non-childbearing potential, sterile, or 
willing to practice adequate contraception from the first 
vaccination to day 85 of the study were included. Beyond 
the general exclusion criteria for an investigational 
study in healthy adults, additional exclusion criteria 
included diagnosis of a deviated nasal septum or nasal 
obstruction, recommendation for annual vaccination 
against influenza or living with or caring for people at 
high risk of influenza-related complications, history of 
influenza vaccination within 6 months before study 
enrolment or unwillingness to forego seasonal influenza 
vaccination, history of vaccination with an investigational 
pandemic influenza vaccine other than an H1N1pdm09 
vaccine, history of excessive daytime sleepiness or 
narcolepsy, history of Guillian-Barré syndrome, history 
of anaphylactic-type reaction to consumption of eggs, or 
history of severe adverse reaction to a previous influenza 
vaccine.
Randomisation and masking
Participants were randomly assigned 4:3:1:3:2 to the 
LAIV8-IIV5/AS03, LAIV8-IIV5, phosphate-buffered saline 
(PBS) placebo, IIV8/AS03-IIV5/AS03, or sterile saline 
placebo groups (figure 1B). Randomisation was blocked 
(block size 13) and stratified by site. The randomisation 
sequence was generated independently by a contract 
research organisation, Emmes Corporation. The study 
nurse enrolled participants and assessed eligibility, and the 
data management system randomly assigned participants 
to groups following entry of data regarding eligibility by 
the study nurse. Eligible participants were entered into 
a dosing cohort within an external data management 
system, which provided a coded treatment number. The 
number was printed and taken to the pharmacist, who was 
unmasked to group assignment. The pharmacist matched 
the coded treatment numbers with the corresponding 
treatment assignments and prepared the study product, 
which they then masked in an opaque plastic sleeve. This 
was an observer-blind study: the participants and study 
staff involved in clinical evaluation of the participants were 
masked to group assignment.
Procedures
The chimeric H8/1N1 LAIV, based on the A/Leningrad/ 
134/17/57 backbone,26 and the chimeric H5/1N1 and 
chimeric H8/1N1 IIV vaccine constructs are described in 
detail elsewhere.18 The LAIV was manufactured in 
embryonated chicken eggs by Meridian Life Science 
(Memphis, TN, USA) and administered intranasally as 
drops at a dose of 10⁷·⁵ (plus or minus ⁰·⁵) 50% egg 
infectious dose, formulated in a total volume of 0·5 mL 
sterile saline. In more detail, the LAIV was delivered 
using a 1 mL syringe without needle. The vaccinee was 
requested to blow their nose before administration and 
to lay supine with their head tilted backward. Half of the 
dose (0·25 mL) was then administered dropwise into one 
nostril by placing the syringe at the entrance of the 
nostril and slowly pressing the plunger of the syringe, 
pointing straight up the vaccinee’s nasal cavity. The 
remaining half of the dose (0·25 mL) was administered 
to the second nostril. The vaccinee was asked not to 
sneeze during administration and was requested to 
remain with their head tilted back for 5 min after 
administration.
The chimeric H5/1N1 and H8/1N1 IIVs were produced 
as split vaccines by GlaxoSmithKline (Wavre, Belgium), 
similar to the vaccines previously described.18,27 The IIVs 
were administered intramuscularly at a dose of 15 μg of 
haemagglutinin in a volume of 0·5 mL of PBS or AS03 as 
adjuvant.
The three vaccine regimens tested were (figure 1B): 
chimeric H8/1N1 LAIV followed by AS03-adjuvanted 
chimeric H5/1N1 IIV (LAIV8-IIV5/AS03 group), chimeric 
H8/1N1 LAIV followed by non-adjuvanted chimeric 
H5/1N1 IIV (LAIV8-IIV5 group), and AS03-adjuvanted 
chimeric H8/1N1 IIV followed by AS03-adjuvanted 
chimeric H5/1N1 IIV (IIV8/AS03-IIV5/AS03 group). The 
first placebo group received 0·5 mL of PBS intramuscularly 
as prime and booster doses (PBS group). The second group 
received 0·5 mL sterile saline intranasally followed by an 
intramuscular injection of 0·5 mL PBS (sterile saline 
group). Individuals who received the LAIV or intranasal 
sterile saline as the prime dose were confined to a con-
tainment unit for at least 5 days after vaccine administration 
and until no shedding of the vaccine virus was detected in 
three consecutive real-time PCR (rtPCR) assays of nasal or 
oropharyngeal swabs collected over 48 h. The cutoff for 
rtPCR assays was cycle threshold value of 40 or less. To 
maintain the observer-blind status of the study, the results 
of inpatient daily influenza A virus tests were provided only 
to a designated unmasked member of the study team. This 
person communicated positive results to the masked 
investigators and study team members on a need to know 
basis (ie, any positive result that might delay discharge 
from the inpatient unit). PCR positive samples were also 
cultured on Mardin Darby canine kidney cells.
Vaccines and placebo treatments were administered 
on study days 1 (chimeric H8/1N1) and 85 (chimeric 
H5/H1N1). Blood samples for this interim analysis were 
taken on study days 1 (day –1 for participants receiving 
LAIV, but indicated as day 1 throughout the manuscript 
for simplicity), 8, 29, 85, 92, and 113 (figure 1B). In this 
pre-planned interim analysis, which was done before the 
complete set of results was available, we assessed serum 
IgG levels to the haemagglutinin stalk and to hetero- 
subtypic full-length haemagglutinins, as well as plasma- 
blast and memory B-cell responses to the haemagglutinin 
stalk and full-length wild-type haemagglutinin.
Following each vaccine administration, participants 
were observed for at least 60 min for any immediate 
adverse reactions. Solicited adverse events recorded for 
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7 days after each vaccination included local reactions at 
the administration site (pain, swelling, and erythema 
after intramuscular administration, or rhinorrhea and 
nasal congestion after intranasal administration) and 
systemic reactions (fever, shivering, headache, fatigue, 
myalgia, arthralgia, cough, sore throat, wheezing, nausea, 
vomiting, abdominal pain, and diarrhoea). Unsolicited 
adverse events were recorded for 28 days after each 
vaccination; all medically attended adverse events, serious 
adverse events, potential immune-mediated diseases, 
influenza-like illnesses, adverse events leading to 
participant withdrawal from the study, and adverse events 
related to abnormal clinical safety laboratory tests were 
recorded throughout the study duration. Safety results 
were blinded to study group and disaggregated safety data 
were not available.
Quantitative serum IgG ELISAs were done according to 
qualified standard operating procedures by NEOMED-
LABS (Laval, Canada). ELISA antigen included a chimeric 
H6/1 recombinant protein that features an H6 head 
domain (strain A/mallard/Sweden/81/02 [H6N1]) fused to 
the same H1 stalk domain as expressed by the vaccines 
(strain A/California/04/09 [H1N1]) but with a stabilising 
mutation.8,28 This substrate was used to measure antibodies 
to the stalk domain of H1 since humans are naive 
to the H6 head domain. Full-length (ecto- domain) 
recombinant haemagglutinin proteins subtype H2 (strain 
A/mallard/Netherlands/5/99 [H2N9]; stalk domain shares 
about 78% aminoacid identity with the stalk domain of the 
H1 vaccine strain), H9 (strain A/chicken/Hong Kong/
G9/97 [H9N2]; stalk domain shares about 59% aminoacid 
identity with the stalk domain of the H1 vaccine strain), 
and H18 (strain A/flat-faced bat/Peru/033/10 [H18N11]; 
stalk domain shares about 65% aminoacid identity with 
the stalk domain of the H1 vaccine strain), which all belong 
to the group 1 haemagglutinins but are phylogenetically 
distant to H1 (figure 1C), were used to determine antibody 
breadth. Titres are expressed as ELISA units (EU) per mL 
and were calculated on the basis of an internal standard to 
which units were arbitrarily assigned.
ELISpots were done on peripheral blood mono- nuclear 
cells (PBMCs) collected 7 days after each vaccination 
(study days 8 and 92) for plasmablast analysis and 
28 days after each vaccination for memory B-cell analysis 
(study days 29 and 113). For memory B-cell responses, 
samples were also collected on study days 1 and 85 and 
analysed to assess cell counts before vaccination. For 
these assays, PBMCs were added to blocked ELISpot plates 
for 16 h overnight in an incubator set at 37°C with 5% CO2. 
After the overnight incubation, plates were washed 
and incubated with anti-IgG-biotin or anti-IgA-biotin 
(Southern Biotechnology, Birmingham, UK) for 1–2  h. 
After secondary antibody incubation, plates were washed 
and incubated with streptavidin-alkaline phosphatase 
(Southern Biotechnology) for 1–2 h. Plates were washed 
and developed with nitro blue tetrazolium/5-bromo-4-
chloro-3-indolyl phosphate (Thermo Fisher Scientific, 
Waltham, USA) for 2–10 min, and reactions were then 
stopped by washing plates with distilled water and allowing 
them to dry overnight before counting. For memory B-cell 
analysis but not plasmablast analysis, to induce memory 
B-cell differentiation into antibody-secreting cells, 1 × 10⁶ 
PBMCs were stimulated with 10 ng/mL lectin pokeweed 
mitogen (Sigma-Aldrich, St Louis, USA), 1:100 000 diluted 
protein A from Staphylococcus aureus, Cowan Strain 
(Sigma-Aldrich, St Louis, USA), and 6 mg/mL CpG 
(Invitrogen, Carlsbad, USA) in an incubator at 37°C with 
5% CO2 for 5 days. After stimulation, cells were counted 
and added to the ELISpot plates. Images were captured 
with Immunocapture 6.4 software, and spots were 
manually counted. Analyses were done using chimeric 
H6/1 and Cal09 H1 haemagglutinin recombinant proteins 
as antigens. Cell counts were expressed as spot-forming 
units per 1 × 10⁶ PBMCs; the limit of detection was four 
spot-forming units.
Outcomes
The primary outcomes were reactogenicity and safety of 
the vaccination regimens. The secondary outcome 
was immunogenicity, including serum IgG and IgA 
to the H1 haemagglutinin stalk domain, serum 
neutralising antibodies to the H1 haemagglutinin stalk 
domain, antibody-dependent cellular cytotoxicity to the 
H1 haemagglutinin stalk domain, and saliva IgG and IgA 
and secretory IgA to the H1 haemagglutinin stalk domain 
28 days after the prime and boost immunisations. 
Additionally, as a secondary outcome, we measured the 
breadth of the immune response (against H2, H9, 
H18 recombinant haemagglutinins, pandemic H1N1, 
and avian-swine H1N1 and H5N8) and its duration. 
Other secondary outcomes included the IgG response to 
N1 neuraminidase and H3 haemagglutinin; cell-mediated 
immune responses; the protective effect of human 
serum in a murine passive transfer-challenge study; and 
haemagglutination inhibition titres against chimeric 
H5/1N1, chimeric H8/1N1, chimeric H6/1N5, and 
pandemic H1N1.
This pre-planned interim analysis reports ELISA, B-cell 
data, and aggregated safety data up to day 113. The 
remaining data is expected to become available with the 
full study report at the end of 2019.
Statistical analysis
Immunogenicity objectives included description of 
seroresponse rates and antibody geometric mean titres. 
Sample sizes of 14 or more evaluable participants per 
group provided more than 80% power for between-group 
comparisons of geometric mean titres using the 
Student’s t test on the log10 scale, assuming geometric 
mean titre ratios of greater than three, with a one-sided 
type I error level of 0·025 and assuming a SD of 0·4 in 
the log10 titres (based on previously published data).29 
Only descriptive statistics were used for this interim 
analysis. We calculated seroresponse rates with two-sided 
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95% exact CIs, and pairing geometric mean titres and 
fold changes with two-sided 95% CIs based on the 
t distribution for the mean of the log-transformed data, 
followed by reversal of the log transformation. Because 
no specific threshold for these assays is known to be 
linked with protection, seroresponses were defined 
arbitrarily as four times or greater increases in titres as a 
descriptive measure. Immunogenicity was assessed 
in the per-protocol population, which included all 
participants without major deviations, including those 
considered likely to affect the immune response. Blinded 
safety analysis was done on all participants that received 
at least one vaccination. Statistical analysis was done 
with SAS software version 9.4.
 This trial is registered with ClinicalTrials.gov, number 
NCT03300050.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Oct 10, 2017, and Nov 27, 2017, 65 participants 
were enrolled and randomly assigned (figure 2). Baseline 
demographic information (aggregated) is provided in 
the appendix (pp 1–2). 20 participants were randomly 
assigned to the LAIV8-IIV5/AS03 group, 15 to the 
LAIV8-IIV5 group, 15 to the IIV8/AS03-IIV5/AS03 
group, ten to the PBS placebo group, and five to the 
sterile saline placebo group. Owing to the small group 
size and participant dropouts in the sterile saline group 
group (final group size was three), the results are not 
reported here.
For the interim analysis, safety results were blinded to 
study group (ie, disaggregated safety data were not 
available). One serious adverse event, a fatal motor vehicle 
accident that was unrelated to study vaccine, was reported. 
Within 28 days of any vaccination, 54 unsolicited adverse 
events were reported in 29 (48%) of the 61 participants. Of 
those, 35 were graded mild in 15 (25%) participants, 
16 were graded moderate in 12 (20%) participants, and 
three were graded severe in two (3%) participants. Of the 
eight unsolicited adverse events reported as related to 
study vaccines, none were graded as severe, three were 
graded as moderate, and the remainder as mild. Medically 
attended adverse events were reported for 13 (21%) of 
61 participants. Solicited local adverse events were 
reported in 12 (48%) of 25 outpatient participants and 
solicited systemic adverse events in 14 (56%) following 
prime immunisation with intramuscular study product. 
Following booster immunisation, solicited local adverse 
events were reported in 18 (32%) of 56 participants and 
solicited systemic adverse events in 21 (38%). Solicited 
local adverse events were reported in 12 (33%) of 
36 participants and solicited systemic adverse events in 
22 (61%) participants following intranasal study product 
administration. No potential immune-mediated diseases 
were reported, and no influenza A infections were 
confirmed in nine reported influenza-like illnesses.
None of the 36 inpatient participants in containment 
had a nasal or oropharyngeal swab positive for influenza A 
virus RNA by real-time PCR the day before administration 
of the chimeric H8/1N1 LAIV or placebo; daily swabs were 
positive in 11 participants on day 2 after administration, 
two on day 3, none on day 4, three on day 5, and none on 
day 6. Cycle threshold values were generally close to the 
cutoff value, indicating low amounts of viral nucleic acid. 
In Madin Darby canine kidney cell culture, aliquots from 
none of the 36 inpatient participants resulted in cytopathic 
effects or stained positive with chimeric H8/1 monoclonal 
antibody.
All study participants had pre-existing H1 stalk baseline 
titres on day 1 with geometric mean titres ranging from 
8 615 to 12 028 EU (figure 3), meaning that all study 
participants were primed. After the first vaccine dose, no 
Figure 2: Trial profile
Randomisation into inpatient (LAIV8-IIV5/AS03, LAIV8-IIV5, and sterile saline placebo control) and outpatient 
(IIV8/AS03-IIV5/AS03 and phosphate buffered saline placebo control) groups is shown. *66 randomly assigned, 
with one ineligible participant included in error and excluded after randomisation.
40 assigned to inpatient groups 1, 2, and 3
3 voluntary withdrawals
1 met exclusion criteria
36 received study vaccine on day 1
1 death (road traffic accident unrelated to 
 study drug)
2 voluntary withdrawals
2 followed up for safety only
 1 received another investigational product
 1 met exclusion criteria
31 received study vaccine on day 85 
1 excluded for out-of-window visit
30 analysed for immunogenicity on day 113
33 analysed for safety on day 113
25 assigned to outpatient groups 4 and 5
25 received study vaccine on day 1
25 received study vaccine on day 85
25 analysed for immunogenicity on day 113
25 analysed for safety on day 113
74 adults assessed for eligibility
9 excluded due to ineligibility 
65 randomly assigned*
See Online for appendix
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increase in anti-H1 stalk antibody titres was observed for 
the LAIV8-IIV5/AS03, LAIV8-IIV5, and placebo groups. 
By contrast, the IIV8/AS03-IIV5/AS03 group had a 
seven times increase (95% CI 4·3–11·4) in anti-stalk 
antibody titres to a geometric mean titre of 84 207 EU 
(63 756–111 219). In this group, 80·0% (51·9–95·7) of 
participants had an increase in titres of four times or 
higher (table) and 33% (11·8–61·6) had at least a ten 
times increase over baseline.
Serum anti-H1 stalk IgG antibody titres for the 
LAIV8-IIV5/AS03, LAIV8-IIV5, and placebo groups 
remained similar to baseline up to study day 85 (figure 3). 
Antibody titres for the IIV8/AS03-IIV5/AS03 group 
declined 2·0 times (95% CI 1·6–2·6) from day 29 to 
day 85 (day 85 geometric mean titre 44 093 EU/mL 
[29 942–64 931]). At day 113, 28 days after the booster 
vaccination, the LAIV8-IIV5/AS03 group had a 5·6 times 
(3·6–8·6) increase in anti-stalk antibody titres over 
baseline. A weaker induction of 2·2 times (1·6–3·2) was 
observed for the LAIV8-IIV5 group. The stalk antibody 
titres for IIV8/AS03-IIV5/AS03 group increased again 
from day 85 by 1·4 times (1·2–1·7; to 4·9 times [95% CI 
3·2–7·5] over baseline). No changes were observed in the 
PBS placebo group. After the booster vaccination, the 
proportion of participants with a at least a four times 
increase above baseline was 73·3% (44·9–92·2) for the 
LAIV8-IIV5/AS03 group, 15·4% (1·9–45·4) for the LAIV8-
IIV5 group, and 57·1% (28·9–82·3) for the IIV8/AS03-
IIV5/AS03 group (table). A ten times or greater increase 
was achieved in 20·0% (4·3–48·1) of the LAIV8-IIV5/
AS03 group, in 14·3% (1·8–42·8) of the IIV8/AS03-IIV5/
AS03 group, and in no patients in the LAIV8-IIV5 group.
At baseline, geometric mean titres of anti-H2 antibodies 
were between 5 597 and 7 554 (figure 3). The results for 
Figure 3: Titres of antibodies targeting the H1 stalk domain and heterosubtypic group 1 haemagglutinins
Geometric mean ELISA antibody titres (ELISA units per mL) are plotted on the y axis (log 10) for the timepoints indicated on the x axis. Error bars show the upper and 
lower limits of the 95% CIs. Vaccination timepoints for the LAIV8-IIV5/AS03, LAIV8-IIV5, IIV8/AS03-IIV5/AS03, and PBS groups are indicated below the x-axis. Group 
sizes are 19 for the LAIV8-IIV5/AS03 group, 14 for the LAIV8-IIV5 group, 15 for the IIV8/AS03-IIV5/AS03 group, and ten for the PBS group. IIV=inactivated influenza 
vaccine. LAIV=live-attenuated influenza vaccine. PBS=phosphate-buffered saline.
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induction of anti-H2 antibodies were similar to the 
results for induction of anti-H1 stalk antibodies. The 
IIV8/AS03-IIV5/AS03 group had an 8·9 times (5·2–15·1) 
increase in anti-H2 antibody titres after the first 
vaccination (geometric mean titre 67 191 [50 322–89 715]), 
a 2·2 times (1·7–2·9) decrease from this peak between 
day 29 and the pre-boost timepoint, and then an increase 
to a geometric mean titre of 41 005 (28 395–59 213) after 
the booster vaccination (day 113; figure 3B). As observed 
for the anti-H1 stalk antibody titres, no response was 
detected after the first vaccination for the LAIV8-IIV5/
AS03 and LAIV8-IIV5 groups (day 29). Following the 
booster vaccination, the LAIV8-IIV5/AS03 group had a 
5·8 times (3·8–8·8) increase over baseline, and a 
2·2 times (1·7–2·9) increase over baseline was reported 
for the LAIV8-IIV5 group at day 113 (figure 3B). 
No induction of anti-H2 antibodies was detected for the 
placebo group. Similar antibody induction patterns for 
the respective vaccine groups were also detected for the 
more distant H9 and H18 subtypes (figure 3).
A plasmablast IgG stalk response to the first vaccine 
dose was induced only in the IIV8/AS03-IIV5/AS03 
group, with a geometric mean cell count at 7 days after 
vaccination of 92·7 spot-forming units per 10⁶ PBMCs 
(95% CI 32·9–261·1) compared with a geometric mean 
cell count below the lower limit of detection of four spot-
forming units per 10⁶ PBMCs in all other groups 
(figure 4A). After the booster dose, geometric mean counts 
of plasmablasts secreting H1 stalk IgG (in spot-forming 
units per 10⁶ PMBCs) were 81·1 (35·3–186·5) in the 
LAIV8-IIV5/AS03 group, 14·4 (4·5–46·0) in the LAIV8-
IIV5 group, 56·5 (26·9–118·7) in the IIV8/AS03-IIV5/
AS03 group, and below the lower limit of detection in the 
PBS control group.
The IgA plasmablast response was weaker than the 
IgG plasmablast response and again detectable only 
for the IIV8/AS03-IIV5/AS03 group after the first 
vaccination (13·8 spot-forming units per 10⁶ PMBCs 
[95% CI 5·2–36·7]; figure 4C). Booster vaccination 
elicited a response in all three vaccine groups 
(21·8 [9·8–48·4] spot-forming units per 10⁶ PBMCs in 
the LAIV8-IIV5/AS03 group, 7·5 [<4·0–19·6] in the 
LAIV8-IIV5 group, and 9·8 [4·6–21·1] in the IIV8/AS03-
IIV5/AS03 group) but not in the placebo group 
(figure 4C). For wild-type Cal09 H1 haemagglutinin, 
we measured IgG-secreting and IgA-secreting cells 
together, and the magnitude of response resembled the 
IgG plasmablast response to the H1 stalk domain 
(figure 4E).
All groups showed baseline IgG and IgA memory 
B-cell reactivity to the haemagglutinin stalk before 
vaccination (figure 4B). Subsets of memory B cells with 
IgG specificities to the stalk domain expanded 28 days 
after prime in all vaccine groups, with the greatest 
increase in the IIV8/AS03-IIV5/AS03 group (figure 4B). 
Increases for LAIV8-IIV5/AS03 and LAIV8-IIV5 groups 
were lower than for the IIV8/AS03-IIV5/AS03 group but 
higher than the fluctuations measured in the PBS control 
group. At day 85 (before boost), levels of memory B cells 
were similar to placebo in all vaccine groups except in the 
IIV8/AS03-IIV5/AS03 group, although the CI does 
overlap with baseline. The number of memory B cells in 
the vaccine groups increased slightly above baseline after 
boost (day 113), but the increase was not comparable to 
the strong response seen in the IIV8/AS03-IIV5/AS03 
group at 28 days after the first vaccination and, again, 
the CIs overlap with baseline. Very little response 
was observed for stalk-reactive IgA memory B cells 
H1 stalk H2 H9 H18
Baseline (before vaccination; seropositive)
LAIV8-IIV5/AS03 19/19, 100·0% (82·4–100·0) 19/19, 100·0% (82·4–100·0) 19/19, 100·0% (82·4–100·0) 19/19, 100·0% (82·4–100·0)
LAIV8-IIV5 14/14, 100·0% (76·8–100·0) 14/14, 100·0% (76·8–100·0) 14/14, 100·0% (76·8–100·0) 14/14, 100·0% (76·8–100·0)
IIV8/AS03-IIV5/AS03 15/15, 100·0% (78·2–100·0) 15/15, 100·0% (78·2–100·0) 15/15, 100·0% (78·2–100·0) 15/15, 100·0% (78·2–100·0)
PBS 10/10, 100·0% (69·2–100·0) 10/10, 100·0% (69·2–100·0) 10/10, 100·0% (69·2–100·0) 10/10, 100·0% (69·2–100·0)
Day 29 (28 days after prime dose; seroresponse)
LAIV8-IIV5/AS03 0/18, 0·0% (0·0–18·5) 0/18, 0·0% (0·0–18·5) 0/18, 0·0% (0·0–18·5) 0/18, 0·0% (0·0–18·5)
LAIV8-IIV5 0/14, 0·0% (0·0–23·2) 0/14, 0·0% (0·0–23·2) 0/14, 0·0% (0·0–23·2) 0/14, 0·0% (0·0–23·2)
IIV8/AS03-IIV5/AS03 12/15, 80·0% (51·9–95·7) 12/15, 80·0% (51·9–95·7) 6/15, 40·0% (16·3–67·7) 6/15, 40·0% (16·3–67·7)
PBS 0/10, 0·0% (0·0–30·8) 0/10, 0·0% (0·0–30·8) 0/10, 0·0% (0·0–30·8) 0/10, 0·0% (0·0–30·8)
Day 113 (28 days after booster dose; seroresponse)
LAIV8-IIV5/AS03 11/15, 73·3% (44·9–92·2) 10/15, 66·7% (38·4–88·2) 5/15, 33·3% (11·8–61·6) 7/15, 46·7% (21·3–73·4)
LAIV8-IIV5 2/13, 15·4% (1·9–45·4) 1/13, 7·7% (0·2–36·0) 1/13, 7·7% (0·2–36·0) 2/13, 15·4% (1·9–45·4)
IIV8/AS03-IIV5/AS03 8/14, 57·1% (28·9–82·3) 10/14, 71·4% (41·9–91·6) 7/14, 50·0% (23·0–77·0) 7/14, 50·0% (23·0–77·0)
PBS 0/10, 0·0% (0·0–30·8) 0/10, 0·0% (0·0–30·8) 0/10, 0·0% (0·0–30·8) 0/10, 0·0% (0·0–30·8)
Values are n/N, % (95% CI). Participants were deemed seropositive at baseline if they had a positive ELISA value. Seroresponse was defined as four times or higher increases 
over baseline in antibodies. IIV=inactivated influenza vaccine. LAIV=live-attenuated influenza vaccine. PBS=phosphate buffered saline.
Table: Frequency of seropositivity at baseline and seroresponses on days 29 and 113 for the H1 stalk domain and heterosubtypic group 1 
haemagglutinins
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(figure 4D). Memory B-cell counts (IgG and IgA 
combined) to the wild type Cal09 H1 of pandemic H1N1 
were generally higher than for H1 stalk IgG at baseline 
but also followed the pattern seen for the anti-stalk IgG 
memory B-cell response (figure 4F).
Discussion
We report the interim results of a phase 1 study with 
the first rationally designed universal influenza virus 
vaccines targeting the haemagglutinin stalk domain. We 
observed that a single vaccination with an adjuvanted 
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Figure 4: Plasmablast and memory B-cell responses to the H1 stalk and wild-type H1 haemagglutinins
The error bars indicate the upper and lower limits of the 95% CIs. The lower limit of detection was four spot forming units per 10⁶ PBMCs. Plasmablasts were tested for 
H1 stalk-specific IgG (A), IgA (C), and Cal09 H1 IgA plus IgG (E) secretion on days 8 and 92 (7 days after vaccination). Memory B cells were tested for H1 stalk-specific 
IgG (B), IgA (D), and Cal09 H1 IgA plus IgG (F) secretion on days 1, 29, 85, and 113 (vaccination timepoints and 4-week post-vaccination timepoints). Group sizes are 
19 for the LAIV8-IIV5/AS03 group, 14 for the LAIV8-IIV5 group, 15 for the IIV8/AS03-IIV5/AS03 group, and ten in the PBS group. IIV=inactivated influenza vaccine. 
LAIV=live-attenuated influenza vaccine. PBMC=peripheral blood mononuclear cells. PBS=phosphate-buffered saline.
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chimeric haemagglutinin-based IIV, but not with a non-
adjuvanted LAIV, induced high serum IgG stalk-reactive 
antibody titres. This initial response to the IIV was 
detected in a vast majority of study participants and was 
heterosubtypic, with confirmed cross-reactivity to H2, 
H9, and H18 haemagglutinins. Given this breadth and 
the phylogenetic distance between H1, H2, H9, and H18, 
the induced response would likely cross-react to all other 
members of the group 1 haemagglutinins. Additionally, 
on the basis of the blinded study group, the vaccine 
regimens were tolerable and no safety concerns were 
observed.
We previously found that high concentrations of stalk-
reactive antibodies in human serum protected mice from 
lethal virus challenge in a passive serum transfer study.30 
Additionally, stalk-reactive serum antibodies were 
correlated with reduced virus shedding and symptom 
numbers in a human challenge model (but not duration or 
severity of symptoms),31 and were shown by Ng and 
colleagues32 to independently correlate with protection 
from natural pandemic H1N1 infection (as defined by PCR 
positivity) and disease in children and adults. Therefore, 
a single dose of chimeric, haemagglutinin-based, 
adjuvanted IIV might induce protective titres against all 
group 1 haemagglutinin-expressing viruses, making it an 
excellent candidate for development as a group 1 pandemic 
vaccine.
Although the induction of anti-stalk serum IgG and 
peripheral blood plasmablast and memory B-cell 
responses by the IIV formulation was obvious, it is less 
clear whether an immune response was induced with a 
chimeric haemagglutinin-based LAIV because no serum 
IgG response was detected after the first vaccination. 
This lack of response might be due to insufficient 
replication of the vaccine virus or an inadequate dose of 
the LAIV. However, seasonal LAIVs administered to 
adults are known to elicit a weak serum antibody 
response but potent mucosal immunity.33,34 It is, there- 
fore, likely that the lack of a serum IgG response is, at 
least partly, a reflection of the inherent properties of the 
vaccine platform. Additionally, pre-pandemic LAIVs, 
including vaccines based on H2, H5, and H6, induced 
no or very weak responses in adults35–37 but primed 
efficiently for strong and broad responses once the same 
individuals were boosted with an IIV of the same 
subtype.21
The booster immunisation with chimeric H5/1N1 IIV 
induced an immune response in most vaccinees, 
including those who had been primed with LAIV or IIV. 
Both the LAIV8-IIV5/AS03 and the IIV8/AS03-IIV5/
AS03 groups showed almost the same titres after the 
booster vaccination, suggesting little priming by the 
initial LAIV dose in terms of serum IgG titres. Adults are 
typically already primed for the stalk domain, as can be 
seen by baseline serum IgG titres and baseline memory 
B-cell levels. The finding of high baseline titres agrees 
with earlier studies that found low but widely prevalent 
pre-existing immunity against the H1 stalk domain in 
adults and even in children, and these titres are usually 
induced by natural infection.8,9,38 Therefore, one potential 
explanation is that the LAIV prime was minimal relative 
to the already existing priming for serum IgG. However, 
it is possible that the LAIV prime leads to higher quality 
serum antibodies (eg, higher affinity or better effector 
functions), a more sustained antibody response, or higher 
titres of mucosal antibodies than priming with the IIV. 
This question remains to be explored as part of the 
extended immune analysis, which will assess mucosal 
immune responses, including mucosal IgG and IgA and 
secretory IgA, and peripheral blood T-cell responses. The 
true strength of this clinical trial might reside in yet to be 
documented mucosal immune responses, so the LAIV 
approach should not be discounted prematurely.
The LAIV8-IIV5 regimen resulted in markedly lower 
titres than the LAIV8-IIV5/AS03 regimen, suggesting that 
an adjuvant is needed for optimal induction of stalk-
reactive antibodies in adults, which is in agreement with 
preclinical findings in mice and ferrets.18,19 Although the 
initial vaccination with adjuvanted chimeric H8/1N1 IIV 
induced a strong immune response to the stalk, the 
booster with chimeric H5/1N1 IIV was not as effective, 
and post-boost antibody concentrations did not exceed 
those achieved after the first dose (for the IIV8/AS03-
IIV5/AS03 group). Potential explanations for this finding 
are that the high titres of stalk-reactive antibodies induced 
by the first vaccination (IIV8/AS03) in this group masked 
or cleared the antigen and blunted the immune response. 
Alternatively, it could be that a response ceiling was 
already reached. A third explanation is that the first 
antigen (chimeric H8/1) was more immunogenic than the 
second (chimeric H8/1), although this was not the case in 
pre-clinical experiments in mouse models.27
With regard to the dynamics of memory B cells, the 
IIV8/AS03 prime induced a strong memory response as 
expected, but this did not occur in the other groups after 
the second dose, despite boosts in plasmablasts and 
antibodies. This finding is notable and could be due to 
several reasons—eg, the peak of the memory B cell 
response might have been missed or memory B-cells 
might have migrated to tissues reducing their numbers in 
peripheral blood. It could also be that the anti-stalk 
memory B-cells might have already peaked with the prime 
immunisation and cannot be boosted further or prime 
and boost might have been too close together diminishing 
the generation of more anti-stalk memory-B cells through 
epitope masking.
This interim analysis has several limitations. The data 
available are limited to the timepoints and assays of the 
per-protocol interim analysis. It includes only two of 
the five key immunological readouts of the study and 
none of the timepoints that would allow analysis of 
antibody persistence. Additional data will become 
available for the full per-protocol analysis and will shed 
more light on the questions discussed above.
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In summary, the interim analysis of this phase 1 trial 
suggests that a chimeric haemagglutinin-based adju- 
vanted IIV induces high titres of anti-stalk antibodies 
that strongly cross-react with heterosubtypic group 1 
haemagglutinins, supporting further development of this 
candidate vaccine as part of a universal influenza virus 
vaccine strategy.
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